From the US healthcare system perspective, atezolizumab and pembrolizumab are likely to be cost-effective at the WTP threshold compared with standard chemotherapy when used in the first-line setting for stage IV NSCLC patients with high PD-L1 expression. Here, CD274 is linked to non-small cell lung carcinoma.